“…In 1985 the French American British (FAB) Cooperative Group published their criteria for diagnosis of megakaryoblastic leukemias or acute my eloid leukemia (AML) M7 [6], Based on these criteria, dc novo AML-M7 is extremely rare in the adult population, and usually associated with blastic transformation of chronic myeloid leukemia (CML) [7,8], Micromegakaryocytic leukemias, on the other hand, are reported in the terminal phase of essential thrombocythemia and myelofibrosis with myeloid metaplasia, as well as associated with other hematological malignancies such as Hodgkin's disease and polycythemia vera [9,10]. Based on morphological criteria micromegakaryocytic leukemia differs from AML-M7 by maturation features, circulating megakaryocytic fragments and thrombocythemia [6,[11][12][13][14].…”